搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 7 天
时间不限
过去 1 小时
过去 24 小时
过去 30 天
按时间排序
按相关度排序
stocknews
17 小时
3 Pharma Stocks to Watch as Gene Therapy Gains Momentum
The pharma market shows promise as gene therapy gains momentum through rapid advancements that address complex diseases and ...
Zacks.com on MSN
22 小时
EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down
Shares of Editas Medicine EDIT plunged 12.5% on Tuesday after announcing that it is seeking a global partner to advance its ...
precisionmedicineonline
23 小时
Editas Seeking Partner or Licensing Deal for Lead Sickle Cell, TDT Gene-Editing Treatment ...
The strategic shift will allow the firm to focus on advancing a newly announced in vivo gene-editing therapy candidate that's in preclinical development.
STAT
1 天
‘Switchable’ CAR-T startup raises $112 million
AvenCell Therapeutics announced that it raised $115 million in a Series B round. The company is developing CAR-T therapies ...
BioPharma Dive
1 天
Editas, changing course again, looks to partner lead CRISPR therapy
The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for ...
1 天
Editas Medicine, Inc. (EDIT) Strategic Update Call Transcript
Editas Medicine, Inc. ( NASDAQ: EDIT) Strategic Update Conference Call October 22, 2024 8:00 AM ET ...
Zacks.com on MSN
1 天
EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies
Editas Medicine, Inc. EDIT announced that it has entered into a collaboration and nonexclusive license agreement with ...
FierceBiotech
2 天
Editas prioritizes in vivo gene therapies, looks to partner reni-cel
Editas Medicine is pushing its in vivo gene therapy strategy to the top of its agenda, boasting proof-of-concept data and ...
2 天
Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo ...
Achieved in vivo preclinical proof of concept of hematopoietic stem and progenitor cell editing by utilizing Editas Medicine’s proprietary ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈